Longvilliers, France

Pascal George

This inventor holds 6 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 9 EPO patents. Top assignees: Sanofi-Aventis, Mitsubishi Pharma Corporation, Sanofi. Active years: 2007-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pascal George. Retrieved from https://idiyas.com/inventor/pascal-george-qaskjntf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 16.7

 

 

Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 28(Granted Patents)


Location History:

  • Saint-Arnoult-en-Yvelines, FR (2007 - 2009)
  • Paris, FR (2013)
  • Longvilliers, FR (2009 - 2014)

Company Filing History:


Years Active: 2007-2025

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of Pascal George

Introduction

Pascal George is an inventor based in Paris, France. He is currently associated with Step Pharma S.a.s., where he contributes to the field of pharmaceutical innovations. Although he has not yet been granted any patents, his work is focused on developing new compounds that could have significant implications in the industry.

Latest Patent Applications

Pascal George's latest patent applications include "Compounds - Compounds of formula (I): and related aspects." This application reflects his ongoing research and development efforts in creating innovative pharmaceutical compounds.

Conclusion

Pascal George is an emerging inventor in the pharmaceutical sector, with a focus on developing new compounds. His contributions, although not yet recognized through granted patents, indicate a promising future in innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…